China Isotope & Radiation (FRA:5IR) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5IR China Isotope & Radiation Corp FRA:5IR
92 GF Score
Price €1.77
GF Value €1.63
! 5 Warning Signs
View Full Analysis

What is China Isotope & Radiation Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:5IR
92GF Score
China Isotope & Radiation Corp FRA:5IR
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is China Isotope & Radiation (FRA:5IR) Overvalued in 2026?

Based on GuruFocus' analysis, China Isotope & Radiation stock appears to be overvalued. The current stock price of €1.77 is trading 8.6% above its estimated GF Value™ of €1.63.

Key valuation signals for FRA:5IR:

  • Cash Payments:
  • GF Value™: €1.63 vs. price of €1.77 (8.6% above fair value)
  • GF Score™: 92/100 with 5 warning signs

No single metric tells the full story. See the FRA:5IR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


China Isotope & Radiation Business Description

Other Exchanges 01763:Hong Kong
Address No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: (1) nuclear medicine; (2) radioactive source products; (3) irradiation; (4) nuclear medical equipment and related services; and (5) other businesses. Nuclear medicines: manufacturing and sale of a range of imaging diagnostic and therapeutic radio pharmaceuticals imaging, UBT diagnostic kits and test analysers and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The company's operations are carried out and a majority of its customers are located in the PRC.
92GF Score

Get the complete analysis for FRA:5IR

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.77
Price
€1.63
GF Value